Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377

Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer

Kim, C. F. B., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., Vogel, S., Crowley, D. G., Bronson, R. T., & Jacks, T. (2005) · Cell · doi:10.1016/j.cell.2005.03.032 · Cited by 2,229

Tumor spectrum analysis in p53-mutant mice

Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605

The Presence of Autonomous and Non-Autonomous Replication in Cancer and their Connection through Inflammation: Lessons from one Lung Cancer Case

Tusung, K. (2019) · Immunome Research · doi:10.35248/1745-7580.19.15.171 · Cited by 2

Animal models and in vivo investigations for drug repurposing in lung cancer

Chang, H.-W. K., & Chang, V. H. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819668-7.00010-5 · Cited by 2

Molecular Basis of Lung Cancer

Sato, M., Shames, D. S., Girard, L., Gazdar, A. F., & Minna, J. D. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10030-5 · Cited by 2

Thoracic Neoplasia: Carcinoma

Politi, K. A., Cruz, C. S. D., & Homer, R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.05310-7 · Cited by 2

Genome-wide identification of CDC34 that stabilizes EGFR and promotes lung carcinogenesisPreprint

Zhao, X., Wang, G., Zhou, Y., Ma, L., Liu, J., Zhang, C., Zhang, D.-L., Gao, S., Qu, L.-W., Zhang, B., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/255844 · Cited by 2

Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformationPreprint

Bowman, R. L., Dunbar, A. J., Mishra, T., Xiao, W., Waarts, M. R., Fernández-Maestre, I., Eisman, S. E., Cai, L., Cai, S. F., Vela, P. S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.18.492524 · Cited by 2

EED Maintains the Small Cell Lung Cancer Neuroendocrine Phenotype and Drives Lung Cancer Histological TransformationPreprint

Li, Y., Laimon, Y. N., Cho, H., Vivero, M., Oliveira, G. R. D., Delcea, A., Savla, V., Chen, Y., Durmaz, Y. T., Qiu, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.07.663486 · Cited by 2

Biochemical Pathways in Cancer

Breuer, E.-K. Y., Murph, M. M., & Craven, R. J. (2012) · Biochemistry Research International · doi:10.1155/2012/268504 · Cited by 1

Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation

Wang, M., Song, Z., Yuan, H., Liu, C., Wang, W., Yang, N., Sun, K., Zhang, S., Qin, X., Li, J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4392 · Cited by 1

Dissecting histological transformation

Earlie, E. M., Gardner, E. E., VARMUS, H. E., & Laughney, A. M. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.02.001 · Cited by 1

Cancer Associated Fibroblasts as Therapeutic Targets

Rupp, C., Dolznig, H., Haslinger, C., Schweifer, N., & Garin‐Chesa, P. (2011) · Springer eBooks · doi:10.1007/978-94-007-0659-0_20 · Cited by 1

Imaging lung cancer in mice models

Coll, J., & Josserand, V. (2006) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2006.09.005 · Cited by 1

Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutations in Three Siblings

Sakakibara, T., Saijo, Y., Fukuhara, T., Gomi, K., Inoue, A., Ishimoto, O., Sugawara, S., & Nukiwa, T. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181653cce · Cited by 1

Genetic Mouse Models of Cancer

Winslow, M. M., & Jacks, T. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10009-3 · Cited by 1

Conformational Transitions in EGFR Protein Tyrosine Kinase Domain and Their Modulation by Mutants

Shaikh, E., Talati, V. P., Garg, D., Baruah, A., Joshi, P., & Bastikar, V. A. (2024) · Proceedings of the National Academy of Sciences India Section B Biological Sciences · doi:10.1007/s40011-024-01605-4 · Cited by 1

Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state

Rominger, M. C., O’Brien, S., Gupta, S., Moorthi, S., McSharry, M. V., Kamlapurkar, S., Lowe, A. R., Waldum, A., Lo, A., Duke, F. F., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116185 · Cited by 1

Preclinical pharmacology and in vivo models

Kèlland, L. R. (2008) · Elsevier eBooks · doi:10.1016/b978-012369448-5.50005-7 · Cited by 1

Lung Cancer Stem Cells

Brainson, C. F., & Kim, C. F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803892-5.00006-1 · Cited by 2

Mouse Models of Receptor Tyrosine Kinases

Holcmann, M., Amberg, N., Drobits, B., Glitzner, E., Komposch, K., Robson, J., Savarese, F., Srivatsa, S., Stulnig, G., & Sibilia, M. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_11 · Cited by 1

Stem Cells and Lung Cancer

Yagui‐Beltrán, A., He, B., & Jablons, D. M. (2009) · Springer eBooks · doi:10.1007/978-0-387-89611-3_8 · Cited by 1

Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation

Ma, E. S. K., & Wong, C. L. P. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8442-3_27 · Cited by 1

DEFINING THE ROLE OF EGFR ACETYLATION IN CELLULAR PROCESSES: CLINICAL IMPLICATIONS

Song, H. (2011) · Digital Commons-TMC (Texas Medical Center) · Cited by 1

Mass Spectrometry in Cancer Research

Veenstra, T. D. (2013) · Wiley eBooks · doi:10.1002/9781118634493.ch2 · Cited by 1

Oncogene Addiction: Mouse Models and Clinical Relevance for Molecularly Targeted Therapies

Alvarez, J. V., Yeh, E. S., Feng, Y., & Chodosh, L. A. (2011) · Springer eBooks · doi:10.1007/978-0-387-69805-2_25 · Cited by 1

Reply to M.C. Garassino et al

Paik, P. K., D’Angelo, S. P., Kris, M. G., & Riely, G. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9025 · Cited by 1

Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib

Bartolazzi, A. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8442-3_20 · Cited by 1

Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine

Berger, A. H., & Pandolfi, P. P. (2011) · Springer eBooks · doi:10.1007/978-0-387-69805-2_27 · Cited by 1

EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer

Eberhard, D. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_20 · Cited by 1

Lungenkrebs: vom Gen zur Therapie

Zander, T., Scheffler, M., Ansén, S., & Wolf, J. (2010) · Onkopipeline · doi:10.1007/s15035-010-0191-7

LOSS OF GPRC5A ENHANCES SURVIVAL IN NORMAL AND MALIGNANT LUNG EPITHELIAL CELLS BY ELICITING PERSISTENT STAT3 ACTIVATION INDUCED BY AUTOCRINE LIF

Chen, Y. (2010) · Digital Commons-TMC (Texas Medical Center)

Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer

Singh, A., Sharma, S. V., & Settleman, J. E. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-088-5_8

THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY

Balko, J. M. (2009) · UKnowledge (University of Kentucky)

Modèles précliniques chez le rongeur de carcinomes pulmonaires

Francoz, S., Mathiaux, J., & Dubus, P. R. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2012.1657

Interrogating Resistance to Targeted Therapy Using Genetically Engineered Mouse Models of Cancer

Gunther, E. J. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-478-4_8

The biological importance of LRIG1 in lung cancer

Kvarnbrink, S. (2012)

Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma

Quigley, B., Ducker, S., & Khalil, F. K. (2013) · Springer eBooks · doi:10.1007/978-94-007-7192-5_4

Optimizing Chemotherapy in Non-Small Cell Lung Cancer

Rosell, R. (2006) · American Journal of Cancer · doi:10.2165/00024669-200605040-00001

Driver mutations as predictive biomarkers in lung cancer

Girard, N. (2012) · Current Respiratory Care Reports · doi:10.1007/s13665-011-0001-x

The expression and molecular functions of LRIG proteins in cancer and psoriasis

Karlsson, T. (2013) · DiVA at Umeå University (Umeå University)

Molecular Basis for the Current Lung Cancer Classification

Borczuk, A. (2012) · Molecular pathology library · doi:10.1007/978-1-4614-3197-8_8

Chimeric Mouse Models for Lung Adenocarcinomas

Chen, Y. (2010) · Future Oncology · doi:10.2217/fon.10.63

Growth factor receptors and tumour development Are they more than just stimulators of tumour growth

Wyckoff, J. B., Condeelis, J. S., & Segall, J. E. (2006)

The Biology of Lung Cancer Stem Cells

Singh, S., & Chellappan, S. (2011) · Springer eBooks · doi:10.1007/978-94-007-2801-1_24

Effects of Radiation Exposure on Lung Carcinogenesis

Delgado, O. (2010)

HER

Köstler, W. J., & Yarden, Y. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.011

Contrôle de la signalisation oncogénique du mutant L858R de l'EGFR par la protéine

Ozenne, P. (2011)

Dottorato di Ricerca in: Organismi Modello Nella Ricerca Biomedica

Veterinaria, E., & Ciclo, X. (2015)

Methods to Study Primary Tumor Cells and Residual Tumor Cells in Mouse Models of Oncogene Dependence

Botta, C., Darini, C., Darrasse-Jèze, G., & Podsypanina, K. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2297-0_19

First-line therapy of advanced non-small cell lung cancer with activatingEGFRmutations

Zhou, C. (2012) · Informa Healthcare eBooks · doi:10.3109/9781841848679.007

A Comprehensive Overview of Mouse Models in Oncology

Vats, D. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527695881.ch6

Mechanisms of IKBKE Activation in Cancer

Challa, S. (2017) · Digital Commons - University of South Florida (University of South Florida)

Comment on prognostic value of epidermal growth factor receptor mutation subtypes in surgically resected non-small cell lung cancer

Kudo, Y., Shimada, Y., Saji, H., & Ikeda, N. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.03.62

The Regulation Of The Expression Of Human Major Histocompatability Class I Molecules On Cancer Cells By Kinases

Brea, E. J. (2016) · eCommons (Cornell University)

Place des thérapeutiques biologiques ciblées

Wislez, M., & Cadranel, J. L. (2008) · ONCOLOGIE · doi:10.1007/s10269-008-0919-y

Hyperactivation of extracellular signal-regulated kinase (ERK) by RAS-mediated signaling or inhibition of dual specificity phosphatase 6 (DUSP6) is associated with toxicity in lung adenocarcinoma cells with mutations in KRAS or EGFRPreprint

Unni, A. M., Harbourne, B., Oh, M. H., Wild, S. A., Lockwood, W. W., & VARMUS, H. E. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/222505

Unravelling Lung Cancer Heterogeneity and Associated Therapeutic Responses using in vivo and ex vivo Model Systems

Nagaraj, A. S. (2018) · Työväentutkimus Vuosikirja

Foxm1 Transcription Factor Regulates Lung Adenocarcinoma Development

Liang, S., Chao, S.-Y., Li, C., Ip, K.-U., Lin, Y.-K., Hsu, C.-C., Hsu, P.-C., & Wang, I. (2019) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/276/1/012003

Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion.

Wu, Q., Chu, M., Hu, J., Zhang, Z., Yi, W., & Ma, X. (2018) · Europe PMC (PubMed Central)

Targeting the EPHA2 receptor tyrosine kinase in KRAS and EGFR mutant lung cancer

Amato, K. R. (2015)

Omics technologies in diagnosis of lung adenocarcinoma

Novikova, S. E., Kurbatov, L. K., Zavialova, M. G., Zgoda, V. G., & Archakov, A. I. (2017) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750817040047

CXCL10/CXCR3 Signaling Contributes to the Oncogenic Pathway in the Development of EGFR-TKI Resistance in EGFR Mutant NSCLCPreprint

Hong, S. H., Kang, N., Kim, O., Hong, S. A., Park, J., Lee, M., & Kang, J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161447

Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue

Dayanc, B., Eris, S., & Şentürk, Ş. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_54

Data from Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling

Kobayashi, S. S., Shimamura, T., Monti, S., Steidl, U. G., Hetherington, C. J., Lowell, A. M., Golub, T. R., Meyerson, M. M., Tenen, D. G., Shapiro, G. I., et al. (2023) · doi:10.1158/0008-5472.c.6495248

Data from Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling

Kobayashi, S. S., Shimamura, T., Monti, S., Steidl, U. G., Hetherington, C. J., Lowell, A. M., Golub, T. R., Meyerson, M. M., Tenen, D. G., Shapiro, G. I., et al. (2023) · doi:10.1158/0008-5472.c.6495248.v1

Vitamin D in the management of lung cancer

Shaurova, T., Calkins, H., Seshadri, M., Johnson, C. S., & Hershberger, P. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91338-6.00040-9

Mechanistic and Clinical Chemoprevention

Moerland, J. A., Chowdhury, A. S., Occhiuto, C. J., Hung, P., & Liby, K. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00058-9

How far have we come in our efforts to apply personalized therapy for lung cancer at bedside?

Kim, H. S., Kim, I. K., Lee, S. B., You, S.-H., Yeo, C. D., Kim, J.-A., Chung, S. H., Lee, S. H., & Kim, H. J. (2024) · Molecular & Cellular Toxicology · doi:10.1007/s13273-024-00500-3

Driver Genes and Genomic Instability Predict the Incidence and Outcome of Brain Metastases

Yang, H., Hong, W., Ding, J., Yuan, W., Ye, H., Lin, T., Hu, Q., Jin, X., Wen, L., Liu, D., et al. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096385277250818184435

Conformational Dynamics of Wild‐Type to Triple Mutant EGFR‐TKD Captured by Coarse‐Grained Simulations

Mir, S. A., Maharana, S. R., Mahapatra, K., Alamri, A., Khan, M. S., Ahmad, I., Meher, R., & Nayak, B. (2025) · ChemistrySelect · doi:10.1002/slct.202501229

Elevated MANF expression in β cells protects mice from streptozotocin-induced diabetes by attenuating islet stress and immunogenicity

Li, H., Danilova, T., Palm, E., Pakarinen, E., Kiva, J., Org, T., Koppinen, T. K., Hakonen, E. T., Teino, I., Voutilainen, M. H., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.043

Impact of particulate matter 2.5 on a mouse model of lung adenocarcinoma

Bektas, E. I., Alam, A., Senchanthisai, S., Mayengbam, S. S., Mackey, E. E., Spitz, E., Alam, S., Atanassov, B. S., Goodrich, D. W., & Dey, P. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04292-1

Twist1 overexpression models an aggressive subtype of pancreatic ductal adenocarcinoma in vivo

Khan, M. A., Chang, J., Song, Y., Shetty, A. C., Nguyen, T., Waters, D. N., Chowdhury, D. D., Simms, E. R., Chan, A., Tseng, H. W., et al. (2026) · Lab Animal · doi:10.1038/s41684-026-01729-2

Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation

Li, Y., Laimon, Y. N., Cho, H., Vivero, M., Oliveira, G. R. D., Seager, M. D., Delcea, A., Savla, V., Chen, Y., Durmaz, Y. T., et al. (2025) · Journal of Clinical Investigation · doi:10.1016/j.jtho.2025.07.028 · Cited by 2

Pattools‑implemented methylation vector analysis reveals aberrant subtype‑specific methylation in lung cancer across tissue and plasma cfDNA

Dong, Z., Luo, Y., Hu, T., Cheng, Y., Ren, Q., Xu, L., Tan, Y., Li, W., Sun, Y., Chen, M., et al. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70812

Longitudinal In Vivo Imaging at Single-Lesion Resolution Identifies Allele-Associated Response and Resistance Dynamics in EGFR-Mutant Lung Cancer

Millán, E. C. S., Panetta, D., Armanetti, P., Quaglierini, M., Zega, A., Mercatelli, R., Bramanti, E., Menichetti, L., Maroni, G., & Levantini, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177727

UTILIZING GENETICALLY ENGINEERED MOUSE MODELS OF PANCREATIC CANCER: EVALUATING THE ROLE OF CATHEPSIN B AND THE EFFICACY OF FARNESYL THIOSALICYLIC ACID

Gopinathan, A. (2010) · ScholarlyCommons (University of Pennsylvania)

Transgenic mice with mouse EGFR mutation developed lung adenocarcinoma

Ohashi, K., Rai, K., Kiura, K., Osawa, M., Hirano, S., Fujiwara, Y., Yoshino, T., Takigawa, N., Takata, M., & Tanimoto, M. (2007) · Cancer Research · Cited by 1

Abstract IA4: Defining the mechanisms of tumorigenesis by mutant EGFR using mouse models

Politi, K. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.12aacriaslc-ia4

Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP‐C promoter

Ohashi, K., Rai, K., Fujiwara, Y., Osawa, M., Hirano, S., Takata, K., Kondo, E., Yoshino, T., Takata, M., Tanimoto, M., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00875.x · Cited by 30

Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors

Regales, L., Balak, M. N., Gong, Y., Politi, K. A., Sawai, A., Le, C. H., Koutcher, J. A., Solit, D. B., Rosen, N. X., Zakowski, M. F., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000810 · Cited by 127

Abstract 725: In vivo imaging and quantitative proteomics to study responsiveness to EGFR targeted therapy.

Venugopalan, A. K., Niu, G., Guo, J., Maity, T. K., Zhang, X., Cultraro, C. M., Chen, X. S., & Guha, U. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-725